Samuel García
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Samuel García has a total of 233 co-authors. Here are the top co-authors by number of shared publications:
- Carmen Conde
Experimental and Observational Rheumatology and Rheumatology Unit, Instituto de Investigacion Sanitaria, Hospital Clínico Universitario de Santiago (IDIS), Santiago de Compostela, Spain
9 shared publications - José María Pego-Reigosa
Department of Rheumatology, University Hospital of Vigo, Vigo, Spain
8 shared publications - Tiago Carvalheiro
Centro do Sangue e da Transplantação de Coimbra, Instituto Português do Sangue e da Transplantação, Coimbra, Portugal
7 shared publications Beatriz Malvar-Fernández
Rheumatology & Immuno-mediated Diseases Research Group (IRIDIS), Galicia Sur Health Research Institute (IIS Galicia Sur), SERGAS-UVIGO
6 shared publications- Carlos Rafael-Vidal
Rheumatology & Immuno-Mediated Diseases Research Group (IRIDIS), Galicia Sur Health Research Institute (IIS Galicia Sur), SERGAS-UVIGO, 36312 Vigo, Spain
6 shared publications Kris A Reedquist
Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, University of Utrecht , Utrecht, The Netherlands
6 shared publications
Latest Publications
- Open Access
- 20 October 2026
- Published by Wiley in Arthritis & Rheumatology
Sema4A neutralization reduces fibrosis and inflammation in a mouse model of systemic sclerosis and a 3D model of immunity‐driven fibrosis
Objective: We previously showed that Semaphorin4A (Sema4A) is elevated in patients with systemic sclerosis (SSc) and promotes inflammation and fibrosis in vitro . Here, we examined the effect of Sema4A neutralization in vivo and in 3D fibrosis models. Methods: Sema4A plasma levels were measured by ELISA in healthy controls (n=31) and patients with SSc (n=30). In the bleomycin SSc‐model, mice were treated with an anti‐Sema4A neutralizing antibody or its respective isotype control (n=6‐7). The 3D fibrosis models, consisting of collagen hydrogel, dermal fibroblasts, and peripheral blood mononuclear cells, were stimulated with recombinant Sema4A, rapamycin, or antibodies neutralizing Sema4A, PlexinD1, PlexinB2, Neuropilin‐1 or their respective isotype controls (n=6‐10). Collagen content was determined by trichrome staining and hydroxyproline assay. Gene expression was determined by RT‐qPCR and obtained from GEO‐NCBI expression arrays, while protein expression by immunohistochemistry, immunoblotting and flow cytometry. Results: Circulating Sema4A was elevated in patients with SSc (p<0.0001), while Sema4A receptors were elevated in SSc skin and lung (p ranged from <0.05 to 0.0001). Anti‐Sema4A administration significantly reduced skin and lung collagen content in bleomycin‐treated mice (p<0.01), as well as the expression of extracellular matrix components, fibrotic and inflammatory mediators, and immune cell infiltration. In the 3D models, SSc serum and SSc PBMCs induced cell contraction, which was drastically abrogated by blocking Sema4A (p<0.01). This effect was associated with reduced expression of fibrotic mediators and attenuated mTORC1 pathway activation. Conclusions: We confirmed the pro‐fibrotic and pro‐inflammatory role of Sema4A, postulating Sema4A neutralization as a novel approach for the treatment of SSc.
- 20 October 2026
- Published by Wiley in Arthritis & Rheumatology
Open AccessSema4A neutralization reduces fibrosis and inflammation in a mouse model of systemic sclerosis and a 3D model of immunity‐driven fibrosis
Objective: We previously showed that Semaphorin4A (Sema4A) is elevated in patients with systemic sclerosis (SSc) and promotes inflammation and fibrosis in vitro . Here, we examined the effect of Sema4A neutralization in vivo and in 3D fibrosis models. Methods: Sema4A plasma levels were measured by ELISA in healthy controls (n=31) and patients with SSc (n=30). In the bleomycin SSc‐model, mice were treated with an anti‐Sema4A neutralizing antibody or its respective isotype control (n=6‐7). The 3D fibrosis models, consisting of collagen hydrogel, dermal fibroblasts, and peripheral blood mononuclear cells, were stimulated with recombinant Sema4A, rapamycin, or antibodies neutralizing Sema4A, PlexinD1, PlexinB2, Neuropilin‐1 or their respective isotype controls (n=6‐10). Collagen content was determined by trichrome staining and hydroxyproline assay. Gene expression was determined by RT‐qPCR and obtained from GEO‐NCBI expression arrays, while protein expression by immunohistochemistry, immunoblotting and flow cytometry. Results: Circulating Sema4A was elevated in patients with SSc (p<0.0001), while Sema4A receptors were elevated in SSc skin and lung (p ranged from <0.05 to 0.0001). Anti‐Sema4A administration significantly reduced skin and lung collagen content in bleomycin‐treated mice (p<0.01), as well as the expression of extracellular matrix components, fibrotic and inflammatory mediators, and immune cell infiltration. In the 3D models, SSc serum and SSc PBMCs induced cell contraction, which was drastically abrogated by blocking Sema4A (p<0.01). This effect was associated with reduced expression of fibrotic mediators and attenuated mTORC1 pathway activation. Conclusions: We confirmed the pro‐fibrotic and pro‐inflammatory role of Sema4A, postulating Sema4A neutralization as a novel approach for the treatment of SSc.
- 2 September 2026
- Published by Springer Nature
- p. 159-175
Arthritis Murine Models for the Study of Inflammation and Pain
- 2 September 2026
- Published by Springer Nature
- p. 159-175
Arthritis Murine Models for the Study of Inflammation and Pain
- Open Access
- 4 February 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17
SEMA3B is associated with disease activity and infliximab response in IBD patients but does not contribute to the development of intestinal inflammation in vivo
Background: Inflammatory bowel disease (IBD) is a chronic inflammatory disorder with increasing worldwide incidence and prevalence. While current treatment options alleviate part of the socioeconomic burden of this disease, new biomarkers and safer therapeutic approaches are needed to combat intestinal inflammation. Class-3 semaphorins (sema3A-3G) have emerged as important regulators of some biological functions underlying inflammation. For instance, SEMA3B protects against tissue damage in arthritis. However, the association of this protein with UC and its involvement in the onset of intestinal inflammation remains elusive. Methods: To close that knowledge gap, we performed a comprehensive transcriptomic analysis of different patient cohorts. Moreover, we investigated the therapeutic efficacy of Sema3B in vivo . Results: Our findings revealed that the expression of SEMA3B was downregulated in IBD patients compared with healthy controls. Similarly, non-responder UC patients to infliximab showed reduced transcript levels of that class-3 semaphorin before receiving the treatment. Unfortunately, the administration of recombinant Sema3B to mice subjected to DSS-acute colitis did not modify the course of the disease. Conclusions: Therefore, SEMA3B appears to be an interesting biomarker in the context of intestinal inflammation, which deserves further validation in larger cohorts. Nonetheless, based on our in vivo results, the implication of this factor in the development of colitis seems to be minimal.
- 4 February 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17
Open AccessSEMA3B is associated with disease activity and infliximab response in IBD patients but does not contribute to the development of intestinal inflammation in vivo
Background: Inflammatory bowel disease (IBD) is a chronic inflammatory disorder with increasing worldwide incidence and prevalence. While current treatment options alleviate part of the socioeconomic burden of this disease, new biomarkers and safer therapeutic approaches are needed to combat intestinal inflammation. Class-3 semaphorins (sema3A-3G) have emerged as important regulators of some biological functions underlying inflammation. For instance, SEMA3B protects against tissue damage in arthritis. However, the association of this protein with UC and its involvement in the onset of intestinal inflammation remains elusive. Methods: To close that knowledge gap, we performed a comprehensive transcriptomic analysis of different patient cohorts. Moreover, we investigated the therapeutic efficacy of Sema3B in vivo . Results: Our findings revealed that the expression of SEMA3B was downregulated in IBD patients compared with healthy controls. Similarly, non-responder UC patients to infliximab showed reduced transcript levels of that class-3 semaphorin before receiving the treatment. Unfortunately, the administration of recombinant Sema3B to mice subjected to DSS-acute colitis did not modify the course of the disease. Conclusions: Therefore, SEMA3B appears to be an interesting biomarker in the context of intestinal inflammation, which deserves further validation in larger cohorts. Nonetheless, based on our in vivo results, the implication of this factor in the development of colitis seems to be minimal.
- Open Access
- 1 July 2025
- Published by Springer Nature in Arthritis Research & Therapy
- Vol. 27 (1) , 1-11
Semaphorin4B is elevated in rheumatoid arthritis and enhances the inflammatory phenotype of macrophages and fibroblast-like synoviocytes
Background: Several members of the class 4 semaphorins are involved in the pathogenesis of rheumatoid arthritis (RA), regulating proinflammatory functions, but the role of (Sema)phorin4B remains unexplored. Therefore, the aim of this study was to determine the expression and function of Sema4B in RA. Methods: Peripheral blood monocytes from healthy controls (HC) and patients with RA were differentiated into M1 macrophages and stimulated with Sema4B and LPS alone and in combination. Fibroblast-like synoviocytes (FLS) from patients with osteoarthritis (OA) and RA and 3D synovium micromasses, formed by RA FLS and RA monocytes, were stimulated with Sema4B and TNF-α alone and in combination. PlexinB2 expression was knocked down using siRNA. Synovial mRNA expression was obtained from gene expression array in GEO-NCBI and determined by (q)uantitative PCR. Protein expression was determined by immunohistochemistry, immunoblotting and ELISA. FLS viability, invasion and migration were determined using calcein, invasion and wound repair scratch assays, respectively. Results: The expression of Sema4B was higher in the synovial tissue of patients with RA, as well as in RA FLS compared to OA FLS. Importantly, the stimulation of RA FLS and RA MØ with inflammatory mediators induced the expression of Sema4B. Functionally, Sema4B alone induced FLS migration and invasion, and enhanced the TNF-α or LPS-induced production of inflammatory mediators (Interleukin (IL)-6, IL-8, TNF-α, CCL-2) and matrix metalloproteases (MMP-1 and MMP-3) in RA FLS, RA MØ and the 3D synovium model. In RA FLS, this effect was mediated by the receptor PlexinB2. Conclusions: In an inflammatory context, Sema4B induces an aggressive FLS phenotype and the production of pro-inflammatory mediators by FLS and MØ. These results suggest that Sema4B is involved in the pathogenic processes observed within the RA synovium.
- 1 July 2025
- Published by Springer Nature in Arthritis Research & Therapy
- Vol. 27 (1) , 1-11
Open AccessSemaphorin4B is elevated in rheumatoid arthritis and enhances the inflammatory phenotype of macrophages and fibroblast-like synoviocytes
Background: Several members of the class 4 semaphorins are involved in the pathogenesis of rheumatoid arthritis (RA), regulating proinflammatory functions, but the role of (Sema)phorin4B remains unexplored. Therefore, the aim of this study was to determine the expression and function of Sema4B in RA. Methods: Peripheral blood monocytes from healthy controls (HC) and patients with RA were differentiated into M1 macrophages and stimulated with Sema4B and LPS alone and in combination. Fibroblast-like synoviocytes (FLS) from patients with osteoarthritis (OA) and RA and 3D synovium micromasses, formed by RA FLS and RA monocytes, were stimulated with Sema4B and TNF-α alone and in combination. PlexinB2 expression was knocked down using siRNA. Synovial mRNA expression was obtained from gene expression array in GEO-NCBI and determined by (q)uantitative PCR. Protein expression was determined by immunohistochemistry, immunoblotting and ELISA. FLS viability, invasion and migration were determined using calcein, invasion and wound repair scratch assays, respectively. Results: The expression of Sema4B was higher in the synovial tissue of patients with RA, as well as in RA FLS compared to OA FLS. Importantly, the stimulation of RA FLS and RA MØ with inflammatory mediators induced the expression of Sema4B. Functionally, Sema4B alone induced FLS migration and invasion, and enhanced the TNF-α or LPS-induced production of inflammatory mediators (Interleukin (IL)-6, IL-8, TNF-α, CCL-2) and matrix metalloproteases (MMP-1 and MMP-3) in RA FLS, RA MØ and the 3D synovium model. In RA FLS, this effect was mediated by the receptor PlexinB2. Conclusions: In an inflammatory context, Sema4B induces an aggressive FLS phenotype and the production of pro-inflammatory mediators by FLS and MØ. These results suggest that Sema4B is involved in the pathogenic processes observed within the RA synovium.
- Open Access
- 16 May 2024
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 63 (12) , 3199-3200
Microbiome status as a predictive tool for response to therapy in rheumatoid arthritis
Samuel García; Microbiome status as a predictive tool for response to therapy in rheumatoid arthritis, Rheumatology, , keae292, https://doi.org/10.1093/rhe
- 16 May 2024
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 63 (12) , 3199-3200
Open AccessMicrobiome status as a predictive tool for response to therapy in rheumatoid arthritis
Samuel García; Microbiome status as a predictive tool for response to therapy in rheumatoid arthritis, Rheumatology, , keae292, https://doi.org/10.1093/rhe
- Open Access
- 12 January 2024
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 14, 1268144
Semaphorin3B promotes an anti-inflammatory and pro-resolving phenotype in macrophages from rheumatoid arthritis patients in a MerTK-dependent manner
Previous works from our group show that Semaphorin3B (Sema3B) is reduced in RA and plays a protective role in a mouse arthritis model. In turn, MerTK plays a protective function in murine arthritis models, is expressed by synovial tissue macrophages and is linked to remission in patients with RA. In this study, we examined the role of Sema3B in the phenotypic characteristics of RA macrophages and the implication of MerTK. Peripheral blood monocytes from RA patients were differentiated into IFN-γ (RA MØIFN-γ) or M-CSF (RA MØM-CSF) macrophages and stimulated with LPS, Sema3B or their combination. Alternatively, RA fibroblast like synoviocytes (FLS) were stimulated with RA MØIFN-γ and RA MØM-CSF supernatants. Gene expression was determined by qPCR and protein expression and activation by flow cytometry, ELISA and western blot. Sema3B down-regulated the expression of pro-inflammatory mediators, in both RA MØIFN-γ and RA MØM-CSF. We observed a similar reduction in RA FLS stimulated with the supernatant of Sema3B-treated RA MØIFN-γ and RA MØM-CSF. Sema3B also modulated cell surface markers in macrophages towards an anti-inflammatory phenotype. Besides, MerTK expression and activation was up-regulated by Sema3B, just as GAS6 expression, Resolvin D1 secretion and the phagocytic activity of macrophages. Importantly, the inhibition of MerTK and neuropilins 1 and 2 abrogated the anti-inflammatory effect of Sema3B. Our data demonstrate that Sema3B modulates the macrophage characteristics in RA, inducing a skewing towards an anti-inflammatory/pro-resolving phenotype in a MerTK-dependant manner. Therefore, here we identify a new mechanism supporting the protective role of Sema3B in RA pathogenesis.
- 12 January 2024
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 14, 1268144
Open AccessSemaphorin3B promotes an anti-inflammatory and pro-resolving phenotype in macrophages from rheumatoid arthritis patients in a MerTK-dependent manner
Previous works from our group show that Semaphorin3B (Sema3B) is reduced in RA and plays a protective role in a mouse arthritis model. In turn, MerTK plays a protective function in murine arthritis models, is expressed by synovial tissue macrophages and is linked to remission in patients with RA. In this study, we examined the role of Sema3B in the phenotypic characteristics of RA macrophages and the implication of MerTK. Peripheral blood monocytes from RA patients were differentiated into IFN-γ (RA MØIFN-γ) or M-CSF (RA MØM-CSF) macrophages and stimulated with LPS, Sema3B or their combination. Alternatively, RA fibroblast like synoviocytes (FLS) were stimulated with RA MØIFN-γ and RA MØM-CSF supernatants. Gene expression was determined by qPCR and protein expression and activation by flow cytometry, ELISA and western blot. Sema3B down-regulated the expression of pro-inflammatory mediators, in both RA MØIFN-γ and RA MØM-CSF. We observed a similar reduction in RA FLS stimulated with the supernatant of Sema3B-treated RA MØIFN-γ and RA MØM-CSF. Sema3B also modulated cell surface markers in macrophages towards an anti-inflammatory phenotype. Besides, MerTK expression and activation was up-regulated by Sema3B, just as GAS6 expression, Resolvin D1 secretion and the phagocytic activity of macrophages. Importantly, the inhibition of MerTK and neuropilins 1 and 2 abrogated the anti-inflammatory effect of Sema3B. Our data demonstrate that Sema3B modulates the macrophage characteristics in RA, inducing a skewing towards an anti-inflammatory/pro-resolving phenotype in a MerTK-dependant manner. Therefore, here we identify a new mechanism supporting the protective role of Sema3B in RA pathogenesis.
- Open Access
- 14 December 2023
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 14, 1277267
Type I Interferons induce endothelial destabilization in Systemic Lupus Erythematosus in a Tie2-dependent manner
Endothelial cell (EC) dysfunction is a hallmark of Systemic Lupus Erythematosus (SLE) and Tie2 is a receptor essential for vascular stability. Inflammatory processes promote inhibition of Tie2 homeostatic activation, driving vascular dysfunction. In this work we determined whether type I Interferons (IFN) induce Tie2 signalling-mediated endothelial dysfunction in patients with SLE. Serum levels of Angiopoietin (Ang)-1, Ang-2 and soluble (s)Tie1 in patients with SLE and healthy controls were measured by ELISA. Monocytes from patients with SLE and Human Umbilical Vein EC (HUVEC) were stimulated with IFN-α, IFN-β (1000 I.U.) or SLE serum (20%). mRNA and protein expression, phosphorylation and translocation were determined by quantitative PCR, ELISA, Western Blot, flow cytometry and confocal microscopy. Viability and angiogenic capacity were determined by calcein and tube formation assays. We found that sTie1 and Ang-2 serum levels were increased and Ang-1 decreased in patients with SLE and were associated with clinical characteristics. Type I IFN significantly decreased Ang-1 and increased Ang-2 in monocytes from patients with SLE. Type I IFN increased sTie1 and Ang-2 secretion and reduced Tie2 activation in HUVEC. Functionally, type I IFN significantly reduced EC viability and impaired angiogenesis in a Tie2 signalling-dependent manner. Finally, SLE serum increased Ang-2 and sTie1 secretion and significantly decreased tube formation. Importantly, Tie1 and IFNAR1 knockdown reversed these effects in tube formation. Overall, type I IFN play an important role in the stability of EC by inhibiting Tie2 signalling, suggesting that these processes may be implicated in the cardiovascular events observed in patients with SLE.
- 14 December 2023
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 14, 1277267
Open AccessType I Interferons induce endothelial destabilization in Systemic Lupus Erythematosus in a Tie2-dependent manner
Endothelial cell (EC) dysfunction is a hallmark of Systemic Lupus Erythematosus (SLE) and Tie2 is a receptor essential for vascular stability. Inflammatory processes promote inhibition of Tie2 homeostatic activation, driving vascular dysfunction. In this work we determined whether type I Interferons (IFN) induce Tie2 signalling-mediated endothelial dysfunction in patients with SLE. Serum levels of Angiopoietin (Ang)-1, Ang-2 and soluble (s)Tie1 in patients with SLE and healthy controls were measured by ELISA. Monocytes from patients with SLE and Human Umbilical Vein EC (HUVEC) were stimulated with IFN-α, IFN-β (1000 I.U.) or SLE serum (20%). mRNA and protein expression, phosphorylation and translocation were determined by quantitative PCR, ELISA, Western Blot, flow cytometry and confocal microscopy. Viability and angiogenic capacity were determined by calcein and tube formation assays. We found that sTie1 and Ang-2 serum levels were increased and Ang-1 decreased in patients with SLE and were associated with clinical characteristics. Type I IFN significantly decreased Ang-1 and increased Ang-2 in monocytes from patients with SLE. Type I IFN increased sTie1 and Ang-2 secretion and reduced Tie2 activation in HUVEC. Functionally, type I IFN significantly reduced EC viability and impaired angiogenesis in a Tie2 signalling-dependent manner. Finally, SLE serum increased Ang-2 and sTie1 secretion and significantly decreased tube formation. Importantly, Tie1 and IFNAR1 knockdown reversed these effects in tube formation. Overall, type I IFN play an important role in the stability of EC by inhibiting Tie2 signalling, suggesting that these processes may be implicated in the cardiovascular events observed in patients with SLE.
- 4 January 2023
- Published by American Chemical Society (ACS) in Biomacromolecules
- Vol. 24 (2) , 667-677
Amphiphilic Phosphorus Dendrons Associated with Anti-inflammatory siRNA Reduce Symptoms in Murine Collagen-Induced Arthritis
Small interfering RNA (siRNA) holds promise for treating rheumatoid arthritis by inhibiting major cytokines such as tumor necrosis factor-alpha (TNF-alpha). We developed original cationic amphiphilic phosphorus dendrons to produce dendriplexes associated with TNF-alpha siRNA. The dendrons were made of 10 pyrrolidinium end groups and a C17 aliphatic chain. The dendriplexes demonstrated the ability to protect siRNA from nuclease degradation and to promote macrophage uptake. Moreover, they led to potent inhibition of TNF-alpha expression in the lipopolysaccharide-activated mouse macrophage cell line RAW264.7 in vitro model. A significant anti-inflammatory effect in the murine collagen-induced arthritis model was observed through arthritis scoring and histological observations. These results open up essential perspectives in using this original amphiphilic dendron to reduce the disease burden and improve outcomes in chronic inflammatory diseases.
- 4 January 2023
- Published by American Chemical Society (ACS) in Biomacromolecules
- Vol. 24 (2) , 667-677
Amphiphilic Phosphorus Dendrons Associated with Anti-inflammatory siRNA Reduce Symptoms in Murine Collagen-Induced Arthritis
Small interfering RNA (siRNA) holds promise for treating rheumatoid arthritis by inhibiting major cytokines such as tumor necrosis factor-alpha (TNF-alpha). We developed original cationic amphiphilic phosphorus dendrons to produce dendriplexes associated with TNF-alpha siRNA. The dendrons were made of 10 pyrrolidinium end groups and a C17 aliphatic chain. The dendriplexes demonstrated the ability to protect siRNA from nuclease degradation and to promote macrophage uptake. Moreover, they led to potent inhibition of TNF-alpha expression in the lipopolysaccharide-activated mouse macrophage cell line RAW264.7 in vitro model. A significant anti-inflammatory effect in the murine collagen-induced arthritis model was observed through arthritis scoring and histological observations. These results open up essential perspectives in using this original amphiphilic dendron to reduce the disease burden and improve outcomes in chronic inflammatory diseases.
- Open Access
- 18 November 2022
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 62 (7) , 2621-2630
HOXA5 is a key regulator of class 3 semaphorins expression in the synovium of rheumatoid arthritis patients
Class 3 semaphorins are reduced in the synovial tissue of RA patients and these proteins are involved in the pathogenesis of the disease. The aim of this study was to identify the transcription factors involved in the expression of class 3 semaphorins in the synovium of RA patients. Protein and mRNA expression in synovial tissue from RA and individuals at risk (IAR) patients, human umbilical vein endothelial cells (HUVEC) and RA fibroblast-like synoviocytes (FLS) was determined by ELISA, immunoblotting and quantitative PCR. TCF-3, EBF-1 and HOXA5 expression was knocked down using siRNA. Cell viability, migration and invasion were determined using MTT, calcein, wound closure and invasion assays, respectively. mRNA expression of all class 3 semaphorins was significantly lower in the synovium of RA compared with IAR patients. In silico analysis suggested TCF-3, EBF-1 and HOXA5 as transcription factors involved in the expression of these semaphorins. TCF-3, EBF-1 and HOXA5 silencing significantly reduced the expression of several class 3 semaphorin members in FLS and HUVEC. Importantly, HOXA5 expression was significantly reduced in the synovium of RA compared with IAR patients and was negatively correlated with clinical disease parameters. Additionally, TNF-α down-regulated the HOXA5 expression in FLS and HUVEC. Finally, HOXA5 silencing enhanced the migratory and invasive capacities of FLS and the viability of HUVEC. HOXA5 expression is reduced during the progression of RA and could be a novel therapeutic strategy for modulating the hyperplasia of the synovium, through the regulation of class 3 semaphorins expression.
- 18 November 2022
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 62 (7) , 2621-2630
Open AccessHOXA5 is a key regulator of class 3 semaphorins expression in the synovium of rheumatoid arthritis patients
Class 3 semaphorins are reduced in the synovial tissue of RA patients and these proteins are involved in the pathogenesis of the disease. The aim of this study was to identify the transcription factors involved in the expression of class 3 semaphorins in the synovium of RA patients. Protein and mRNA expression in synovial tissue from RA and individuals at risk (IAR) patients, human umbilical vein endothelial cells (HUVEC) and RA fibroblast-like synoviocytes (FLS) was determined by ELISA, immunoblotting and quantitative PCR. TCF-3, EBF-1 and HOXA5 expression was knocked down using siRNA. Cell viability, migration and invasion were determined using MTT, calcein, wound closure and invasion assays, respectively. mRNA expression of all class 3 semaphorins was significantly lower in the synovium of RA compared with IAR patients. In silico analysis suggested TCF-3, EBF-1 and HOXA5 as transcription factors involved in the expression of these semaphorins. TCF-3, EBF-1 and HOXA5 silencing significantly reduced the expression of several class 3 semaphorin members in FLS and HUVEC. Importantly, HOXA5 expression was significantly reduced in the synovium of RA compared with IAR patients and was negatively correlated with clinical disease parameters. Additionally, TNF-α down-regulated the HOXA5 expression in FLS and HUVEC. Finally, HOXA5 silencing enhanced the migratory and invasive capacities of FLS and the viability of HUVEC. HOXA5 expression is reduced during the progression of RA and could be a novel therapeutic strategy for modulating the hyperplasia of the synovium, through the regulation of class 3 semaphorins expression.
- Open Access
- 13 April 2022
- Published by Wiley in Arthritis & Rheumatology
- Vol. 74 (6) , 972-983
Central Role of Semaphorin 3B in a Serum‐Induced Arthritis Model and Reduced Levels in Patients With Rheumatoid Arthritis
Objective: Semaphorin 3B (Sema3B) decreases the migratory and invasive capacities of fibroblast‐like synoviocytes (FLS) in rheumatoid arthritis (RA) and suppresses expression of matrix metalloproteinases. We undertook this study to examine the role of Sema3B in a mouse model of arthritis and its expression in RA patients.Methods: Clinical responses, histologic features, and FLS function were examined in wild‐type (WT) and Sema3B−/− mice in a K/BxN serum transfer model of arthritis. Protein and messenger RNA expression of Sema3B in mouse joints and murine FLS, as well as in serum and synovial tissue from patients with arthralgia and patients with RA, was determined using enzyme‐linked immunosorbent assay, immunoblotting, quantitative polymerase chain reaction, and RNA sequencing. FLS migration was determined using a wound closure assay.Results: The clinical severity of serum‐induced arthritis was significantly higher in Sema3B−/− mice compared to WT mice. This was associated with increased expression of inflammatory mediators and increased migratory capacity of murine FLS. Administration of recombinant mouse Sema3B reduced the clinical severity of serum‐induced arthritis and the expression of inflammatory mediators. Sema3B expression was significantly lower in the synovial tissue and serum of patients with established RA compared to patients with arthralgia. Serum Sema3B levels were elevated in patients with arthralgia that later progressed to RA, but not in those who did not develop RA; however, these levels drastically decreased 1 and 2 years after RA development.Conclusion: Sema3B expression plays a protective role in a mouse model of arthritis. In RA patients, expression levels of Sema3B in the serum depend on the disease stage, suggesting different regulatory roles in disease onset and progression.
- 13 April 2022
- Published by Wiley in Arthritis & Rheumatology
- Vol. 74 (6) , 972-983
Open AccessCentral Role of Semaphorin 3B in a Serum‐Induced Arthritis Model and Reduced Levels in Patients With Rheumatoid Arthritis
Objective: Semaphorin 3B (Sema3B) decreases the migratory and invasive capacities of fibroblast‐like synoviocytes (FLS) in rheumatoid arthritis (RA) and suppresses expression of matrix metalloproteinases. We undertook this study to examine the role of Sema3B in a mouse model of arthritis and its expression in RA patients.Methods: Clinical responses, histologic features, and FLS function were examined in wild‐type (WT) and Sema3B−/− mice in a K/BxN serum transfer model of arthritis. Protein and messenger RNA expression of Sema3B in mouse joints and murine FLS, as well as in serum and synovial tissue from patients with arthralgia and patients with RA, was determined using enzyme‐linked immunosorbent assay, immunoblotting, quantitative polymerase chain reaction, and RNA sequencing. FLS migration was determined using a wound closure assay.Results: The clinical severity of serum‐induced arthritis was significantly higher in Sema3B−/− mice compared to WT mice. This was associated with increased expression of inflammatory mediators and increased migratory capacity of murine FLS. Administration of recombinant mouse Sema3B reduced the clinical severity of serum‐induced arthritis and the expression of inflammatory mediators. Sema3B expression was significantly lower in the synovial tissue and serum of patients with established RA compared to patients with arthralgia. Serum Sema3B levels were elevated in patients with arthralgia that later progressed to RA, but not in those who did not develop RA; however, these levels drastically decreased 1 and 2 years after RA development.Conclusion: Sema3B expression plays a protective role in a mouse model of arthritis. In RA patients, expression levels of Sema3B in the serum depend on the disease stage, suggesting different regulatory roles in disease onset and progression.